Italy
· Delayed Price · Currency is EUR Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of EUR 3.93 billion. The enterprise value is 3.79 billion.
| Market Cap | 3.93B |
| Enterprise Value | 3.79B |
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +16.01% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 118.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 220.07 |
| PB Ratio | -30.03 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.66 |
| EV / Sales | 232.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.82 |
Financial Position
The company has a current ratio of 6.17
| Current Ratio | 6.17 |
| Quick Ratio | 6.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.31 |
| Interest Coverage | -6.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.11% |
| Return on Invested Capital (ROIC) | -57.92% |
| Return on Capital Employed (ROCE) | -43.88% |
| Revenue Per Employee | 35,831 |
| Profits Per Employee | -1.14M |
| Employee Count | 498 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.56 |
Income Statement
In the last 12 months, Cytokinetics had revenue of EUR 17.84 million and -569.42 million in losses. Loss per share was -5.09.
| Revenue | 17.84M |
| Gross Profit | -309.99M |
| Operating Income | -517.96M |
| Pretax Income | -569.42M |
| Net Income | -569.42M |
| EBITDA | -508.76M |
| EBIT | -517.96M |
| Loss Per Share | -5.09 |
Balance Sheet
The company has 1.04 billion in cash and 891.70 million in debt, giving a net cash position of 147.62 million.
| Cash & Cash Equivalents | 1.04B |
| Total Debt | 891.70M |
| Net Cash | 147.62M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -130.76M |
| Book Value Per Share | -1.11 |
| Working Capital | 896.61M |
Cash Flow
In the last 12 months, operating cash flow was -382.39 million and capital expenditures -3.77 million, giving a free cash flow of -386.16 million.
| Operating Cash Flow | -382.39M |
| Capital Expenditures | -3.77M |
| Free Cash Flow | -386.16M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,902.72% |
| Pretax Margin | -3,191.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.01% |
| Shareholder Yield | -16.01% |
| Earnings Yield | -14.50% |
| FCF Yield | -9.83% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cytokinetics has an Altman Z-Score of -0.53. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.53 |
| Piotroski F-Score | n/a |